Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Boehringer Ingelheim1,293 enrolled

Overview

Study to obtain information about the co-operation of the different physician-colleagues in the treatment of patients with Parkinson's disease, both in private practices and clinics and about the primary treatment strategies in the pharmacotherapy of Parkinson's disease and to collect data on the tolerability of Sifrol® in ambulatory patients suffering from Parkinson's disease under routing conditions

Study Type

OBSERVATIONAL

Enrollment

1,293

Conditions

Parkinson Disease

Interventions

PramipexoleDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with Parkinson's disease who present to the specialist neurologist practice for the first time without or with referral and who are planned to receive or either be switched to Sifrol or continue the previously prescribed therapy with Sifrol® can be included in this observational study Exclusion Criteria: * Neurologists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

Outcomes

Primary Outcomes

Global Assessment of efficacy by investigator on a 4-point scale

Time frame: after 8 weeks

Change from Baseline in actual Parkinson symptoms

Time frame: Baseline, after 8 weeks

Global Assessment of tolerability by investigator on a 4-point scale

Time frame: after 8 weeks

Secondary Outcomes

Number of patients with adverse drug reactions

Time frame: up to 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.